---
title: "Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations"
canonical: "https://www.renown.org/clinical-trials-directory/NCT02523014"
last_updated: "2026-10-01T01:26:37Z"
---

# Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

URL: https://www.renown.org/clinical-trials-directory/NCT02523014

Short Title: A071401

Enrollment Status: Recruiting

NCT #: [NCT02523014](https://clinicaltrials.gov/study/NCT02523014)

Specialty Area: Oncology

Conditions Studied: Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation

Age Groups: Adult; Older Adult

Sex: All

Study Type: Interventional

Accepts Healthy Volunteers: No

Phase: II

Principal Investigator: Mauricio Perez Davila, MD

Complete Study Details: https://clinicaltrials.gov/study/NCT02523014

## Study Information

### Summary / Purpose

The purpose of this study is to see how well capivasertib and abemaciclib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). This trial is trying to see if tumor genetic testing would be helpful at guiding treatment.

### Who Can Participate

- Adults 18+ years of age
- Must have histologically confirmed intracranial meningioma, progressive or residual disease
- Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain in tumor sample

### What's Involved

- Assignment to receive the study drug given orally
- Participate in follow up every 6 months for up to 5 years

## Additional Information

Location: Renown Health, Office of Clinical Research

Address: 1500 E 2nd St. Reno, NV 89502

General Research: [775-982-3646](tel:775-982-3646)

Oncology Research: [775-982-5050](tel:775-982-5050)

Email: [Renown-CRD@renown.org](mailto:Renown-CRD@renown.org)
